AbbVie has announced encouraging late-breaking results from its Phase 2 IMGN853-0420 clinical trial, showcasing the potential of mirvetuximab soravtansine-gynx in treating recurrent platinum-sensitive ovarian cancer (PSOC). The findings are being presented during an oral session at the Society of Gynecologic Oncology Annual Meeting 2026 held in San Juan, Puerto Rico.
The study evaluated mirvetuximab soravtansine-gynx, a first-in-class antibody-drug conjugate (ADC), in combination with carboplatin, followed by maintenance monotherapy using the same agent. The trial enrolled 125 patients with folate receptor alpha (FRα)-positive ovarian cancer who had previously received one line of platinum-based chemotherapy.
Results from the study demonstrated strong clinical activity. The confirmed objective response rate (ORR) reached 62.7% in patients with higher FRα expression (≥50%) and 62.4% across the broader study population (≥25% FRα expression) after the initial combination treatment phase. Notably, 81% of patients showed no disease progression and transitioned to maintenance therapy with mirvetuximab soravtansine-gynx alone.
Further benefits were observed during the continuation phase, where patients receiving monotherapy achieved an ORR of 68%. The median duration of response across the overall population was reported at 11.2 months, indicating sustained treatment benefit. Importantly, nearly half of the patients had prior exposure to polymerase inhibitors (PARPi), a group often associated with reduced responsiveness to subsequent therapies. Despite this, the ORR in this subgroup remained high at 63.9%.
Safety findings from the trial were consistent with previous studies of the drug. The most common treatment-related adverse events were low-grade ocular issues, including reversible corneal changes in the majority of cases. More severe adverse events included neutropenia, blurred vision, thrombocytopenia, cataracts, dry eye, diarrhea, and peripheral sensory neuropathy.
According to Daejin Abidoye, platinum-sensitive ovarian cancer remains difficult to manage despite its responsiveness to chemotherapy, as repeated treatments often lead to diminishing returns and increased toxicity. He noted that the trial results further support the potential of mirvetuximab soravtansine-gynx as a novel treatment approach.
Lead investigator Gottfried E. Konecny highlighted the significance of combining antibody-drug conjugates with standard chemotherapy, particularly for patients with limited options after prior treatments such as PARP inhibitors.
While the findings are promising, mirvetuximab soravtansine-gynx in combination with carboplatin is not yet approved in the United States, the European Union, or other regions. Further studies will be needed to confirm its safety and efficacy before regulatory approval can be sought.
The presentation underscores AbbVie’s continued focus on advancing targeted therapies in oncology and addressing unmet needs in ovarian cancer treatment.